A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02758041

Enrollment

Registered

2016-05-02

Start date

2016-02-29

Completion date

2017-02-28

Last updated

2017-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facial Acne Vulgaris

Keywords

Acne

Brief summary

This study is proposed to evaluate Sebacia Microparticle treatment in patients with facial inflammatory acne vulgaris.

Interventions

DEVICESebacia Microparticles

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

16 Years to 45 Years

Healthy volunteers

Inclusion criteria

1. Male or female, 16-45 years of age. 2. Moderate to moderately-severe facial inflammatory acne vulgaris 3. Fitzpatrick skin phototype I-III

Exclusion criteria

1. Pregnant, lactating, nursing or planning to become pregnant 2. Tattoo in the treatment area 3. Active skin disease, excessive scarring or excess facial hair in the treatment area 4. Certain current or recent acne treatments 5. Recent light treatments including Intense Pulsed Light or other lasers, microdermabrasion or chemical peels in the treatment area 6. Contraindicated for laser treatment, or is unable or unwilling to avoid excessive sun exposure or tanning bed use 7. Known allergy to gold

Design outcomes

Primary

Measure	Time frame
Percent reduction in lesion count from baseline	Baseline, Week 12, Week 24, Week 36

Secondary

Measure	Time frame
Improvement in Investigator Global Acne Score	Baseline, Week 12, Week 24, Week 36

Countries

Denmark, Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026